InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies [Yahoo! Finance]
InMed Pharmaceuticals Inc. - Common Shares (INM)
Company Research
Source: Yahoo! Finance
In Vivo studies demonstrate INM-901 reduces neuroinflammation and improves neuronal function Molecular analysis data further explains previously reported observations in behavioral studies on locomotion, memory and cognition Vancouver, British Columbia--(Newsfile Corp. - April 4, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced additional preclinical data demonstrating INM-901's positive pharmacological effects in the potential treatment of Alzheimer's disease ("AD"). Dr. Eric Hsu, Senior Vice President of Preclinical Research and Development at InMed, stated, "The recent results demonstrating pharmacological effects in in vivo disease models continue to validate INM-901 as a potential treatment of AD. We are particularly encouraged with indications that INM-901 has multiple potential mechanisms of action as a pre
Show less
Read more
Impact Snapshot
Event Time:
INM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INM alerts
High impacting InMed Pharmaceuticals Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
INM
News
- InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board [Yahoo! Finance]Yahoo! Finance
- InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration [Yahoo! Finance]Yahoo! Finance
- InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance [Yahoo! Finance]Yahoo! Finance
- InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
INM
Sec Filings
- 4/18/24 - Form 8-K
- 4/16/24 - Form 8-K
- 4/5/24 - Form 8-K
- INM's page on the SEC website